Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Liver transplantation has faced unprecedented challenges since the emergence of SARS-CoV-2 in Wuhan (China). In the US, numbers of living and deceased donor liver transplants (LTs) performed weekly decreased significantly from January to March 2020 [1]. Although numbers have risen roughly back to pre-pandemic levels in July and August 2020, the emergence of new COVID-19 variants such as the B.1.1.7 variant in the UK is expected to cause new disruptions to transplant activity.

Many questions regarding the association between COVID-19 and LT remain unresolved. One of them is graft injury induced by COVID-19 and the need for re-transplantation. Liver abnormality is identified as a possible sequela of COVID-19 infection. Biochemical abnormalities and liver injury are detected respectively in 27.3% (n = 227) and 3.9% (n = 32) of a Wuhan-based cohort of COVID-19 patients in general [2]. Most cases are attributable to severe COVID-19. A systematic review found that the pooled ORs of ALT elevation was 2.5, AST elevation was 3.4, and hyperbilirubinaemia was 1.7 amongst critically ill COVID-19 patients [3]. The presence of liver abnormalities in COVID-19 patients regardless of prior liver health makes us contemplate the extent and form of these changes in LT patients with COVID-19.

LT patients with COVID-19 can experience more severe disease than their non-transplant counterparts. According to Colmenero and colleagues [4], respectively 86.5% (n = 96) and 31.5% (n = 35) were hospitalised and met the criteria for severe COVID-19. The trends were corroborated by the results presented by Rabiee and colleagues [5], where 72.3 (n = 81) patients were hospitalised and 37.0% (n = 30) were admitted to the intensive care unit (ICU). Such studies, performed at the early stages of the pandemic, are prone to selection bias and lack comparator groups. However, according to two systematic reviews [6,7], ICU admission is higher in COVID-19 patients having received solid organ transplantation before. Higher disease severity is expected. By logic, there should be higher risk for LT patients to experience liver injury.

However, few data confirm the correlation, let alone establish the disease course. It is unknown whether liver abnormalities in transplant patients are transient or irreversible and, if the former, how long it takes for liver function parameters to normalise. Current evidence is optimistic. Colmenero and colleagues found that only 2.7% (n = 3) of LT patients with COVID-19 developed graft dysfunction [4]. None experienced graft loss. A US cohort [5] found 34.8% experienced re-transplantation in liver transplant patients with COVID-19.

Keywords: COVID-19, liver transplant, graft injury, re-transplantation, chronic liver disease

© 2021 The Author(s). Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

ARTICLE INFO

Article History:
Received 17 March 2021
Revised 14 April 2021
Accepted 17 April 2021
Available online 23 April 2021

Abstract

This article discusses the current scene of liver transplantation (LT) in light of the impact of COVID-19, with particular emphasis on the possibility of graft injury and re-transplantation in LT patients infected with SARS-CoV-2. A major concern is whether such patients experience a more severe form of disease which may lead to a higher risk of acute, irreversible liver injury. If this is serious, it may necessitate re-transplantation. This article aims to raise awareness in this relatively under-researched domain. More studies are required to evaluate this issue since it has strong implications in healthcare resource allocation and clinical decision-making. Several potential research directions are proposed, including the possibility of prolonging bridging therapy for non-urgent LT cases: patients with hepatocellular carcinoma; and whether hepatoprotective agents play a role in liver-sparing during SARS-CoV-2 infection. There is also substantial discussion of the relevance of lung injury in LT patients with COVID-19 since it is not uncommon regarding the high expression of ACE2 receptors in the lungs, and that lung injury remains the major cause of death in patients with chronic liver disease.

Alexander Ng*
University College London, Gower Street, London, United Kingdom

* Corresponding author.
E-mail address: a.ng.20@ucl.ac.uk

Abbreviations: ACE2, angiotensin-converting enzyme 2; ALT, alanine transaminase; AST, aspartate transaminase; BCLC, Barcelona Clinic Liver Cancer Staging; COVID-19, coronavirus disease 2019; DEB, drug-eluting beads; ICU, intensive care unit; JAK, Janus Kinase; LT, liver transplant; OR, odds ratio; TACE, transarterial chemoembolization; US, United States; UDCA, Ursodeoxycholic acid

There is no funding source to declare.
There are no conflicts of interest to declare.
The sole author is responsible for all aspects of the production of the manuscript.
There are no acknowledgements. No ethics approval is required.

https://doi.org/10.1016/j.liver.2021.100008
2666-9676/© 2021 The Author(s). Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
liver injury, with significant increases in ALT (median, 23 vs 32 IU/L; p < 0.001) and AST (median, 19 vs 41 IU/L; p < 0.001) from baseline. The study also examined changes in liver function parameters in patients with clinical resolution of COVID-19. Such parameters were significantly decreased from peak levels (ALT: 40.3 vs 29.8; p = 0.06; AST: 44.9 vs 29.0; p = 0.005). However, they remained higher than baseline. It is unknown whether they would ever return to baseline and, if yes, when. A longer follow-up period is therefore required to tease out these changes. Moreover, the heterogeneity of COVID-19 severity in the cohort may have underestimated the impact of COVID-19 on liver function, especially in patients with severe disease. Nevertheless, this theory is not without caveat. Bangash and colleagues suggested that aminotransferase elevations may originate from myositis due to concurrent rises in myoglobin and creatine kinase, instead of hepatic dysfunction [8]. Furthermore, innate immunity dysregulation and the presence of virally induced cytotoxic T cells are suggested to be more important explanations. The authors postulated that, as observed in other respiratory viruses, aminotransferase level elevations change according to respiratory disease course without hepatic viral replication. However, more recent academic opinion suggests there is higher risk that pathological changes within the livers of patients with severe COVID-19, including microvasculature thrombosis and hepatic steatosis are irreversible [9]. This leads to persistently elevated aminotransferase levels. More studies are required to confirm this correlation.

There are several remarks concerning observational studies on LT patients with COVID-19. Most studies are regional, carried out in the Western hemisphere, and feature small cohorts of limited diversity. Furthermore, transplant-to-infection times tend to be long. A more thorough assessment of the relationship between COVID-19 and the acute complications of LT, including hepatocellular injury secondary to graft rejection, is still wanting. There is also scarce literature on the prevalence and indication(s) of re-transplantation in LT patients with a history of COVID-19. Such studies are urgently required for better resource allocation and reducing pressure on healthcare facilities. Re-transplantation, for instance, poses pressure on organ supply, which is diminished with enhanced COVID-19 screening in donors [10].

Two potential research directions are proposed: (1) whether hepato-protective agents play a potentially significant role in liver-sparing amidst COVID-19 in LT patients, and (2) whether bridging therapy for non-urgent, transplant-eligible patients with hepatocellular carcinoma can delay transplantation for longer periods of time. Ursodeoxycholic acid (UDCA), and N-acetylcysteine are shown to display hepatoprotective effects. According to a small randomised controlled trial [11], UDCA treatment effectively reduced liver enzymes in patients with normal baseline ALT levels at four weeks of follow-up. It was shown to regulate uraemic toxins, antioxidants, and the phenylalanine/tyrosine pathway. However, the data remain controversial [12]. Trials investigating the efficacy of UDCA in LT patients with COVID-19 to mitigate liver injury are recommended. Data on the efficacy of N-acetylcysteine are scarce and controversial. Early animal models indicate its amelioration of ischaemia/reperfusion injury, which is a key mechanism of liver injury in COVID-19, but a randomised controlled trial showed no improvement on graft function post-transplantation [13,14]. Clinical trials are needed to elucidate its effects on LT patients with COVID-19. In terms of bridging therapy, locoregional therapies are pivotal in reducing disease progression in transplant-eligible patients with hepatocellular carcinoma. Transarterial chemoembolisation (TACE) with drug-eluting beads (DEB) was found to elicit a complete response in over half (58%) of patients with BCLC-A hepatocellular carcinoma [15]. The response was maintained for seven months in over one-third of the cohort (31%). LT eligibility was maintained for a median of 19 months. Further studies could be executed to see if this delay could be lengthened by varying current regimens, thus improving healthcare resource allocation.

One should also not forget the importance of lung injury in LT patients with COVID-19. Efforts to treat liver injury should complement existing treatment paradigms to cope with lung injury, since COVID-19-related lung injury is the most common cause of mortality in COVID-19 patients with chronic liver disease. This is evidenced by the findings of Marjot, Moon and colleagues, where only 19% of all deceased patients died of lung-related complications [16]. Moreover, concomitant lung and liver injury amidst COVID-19 is not uncommon. According to Li and colleagues, the levels of expression of ACE2 receptors in the lungs and the liver are similar [17]. Fortunately, trials are underway to explore the efficacy of immunosuppressants in mitigating the harms resultant from lung injury. The TACROVID trial investigated the clinical utility of methylprednisolone pulses and tacrolimus in treating patients with severe COVID-19 pneumonia [18]. Of interest, the combination is found to be beneficial. Where tacrolimus-based immunosuppression does exhibit an advantage in mitigating lung injury, clinicians may be more inclined to continue immunosuppression by switching to, or maintaining the use of, tacrolimus. Moreover, the RuXoCoil trial aims to investigate the efficacy of ruxolitinib, a JAK1/2 inhibitor, in reducing the extent of lung injury experienced by patients with COVID-19 [19]. Trial results are pending, but the efforts of the trial investigators should be commended. Adding ruxolitinib, or other JAK inhibitors to the immunosuppression regimen in LT patients with COVID-19 is potentially beneficial due to further amelioration of pulmonary health during the disease course. Although JAK inhibitor-induced hyperlipidaemia may raise a concern in patients whose indication for LT is metabolic-associated fatty liver disease (with many patients suffering from predisposing patie metabolic syndrome) [20], this can be monitored regularly and controlled by polypharmacy such as statins, if necessary. More studies are also required to elucidate on the interactions between JAK inhibitors and existing immunosuppressants for LT patients safe for use in COVID-19.

Table 1

| Origin                  | Colmenero et al. (2020) [4] | Rabiee et al. (2020) [5] | Webb et al. (2020) [21] | Dumortier et al. (2021) [22] | Becchetti et al. (2020) [23] |
|-------------------------|-----------------------------|--------------------------|--------------------------|-----------------------------|-----------------------------|
| Age, years              | 65 (54–76)                  | 61 (51–71)               | 60 (47–66)               | 64 (55–71)                  | 65 (57–70)                  |
| Male                    | 79 (71%)                    | 61 (55%)                 | 102 (68%)                | 64 (70%)                    | 40 (70%)                    |
| Smoker                  | NR                          | 44 (39%)                 | 3 (2%)                   | 13 (14%)                    | 7 (12%)                     |
| White ethnicity         | NR                          | 31 (28%)                 | 111 (74%)                | 103 (93%)                   | 53 (93%)                    |
| Hospitalisation (%)     | 96 (87%)                    | 81 (72%)                 | 124 (82%)                | 67 (74%)                    | 41 (72%)                    |
| Median Duration of Hospital Stay, days | 7 (4–10)                   | 11 (6–16)                | NR                       | 10 (7–22)                   |                             |
| Mechanical Ventilation given (%) | 22 (20%)                  | 26 (23%)                 | 30 (20%)                 | 33 (36%)                    | 30 (54%)                    |
| Admission to ICU (%)    | 12 (11%)                    | 30 (27%)                 | 43 (28%)                 | 33 (36%)                    | 4 (7%)                      |
| Overall Mortality (%)   | 20 (18%)                    | 25 (22%)                 | 28 (19%)                 | 20 (22%)                    | 7 (12%)                     |
LT in the era of COVID-19 is challenging. Nevertheless, the obstacles are not insurmountable.

Data are either presented as medians (inter-quartile range) or n (%). All figures are rounded to the nearest integer. All percentages are calculated with the cohort size given as the denominator. Non-transplant comparison cohorts are not included in this table. Colmenero et al. (2020), and Dumortier et al. (2020) calculated a composite end-point (admission to ICU, mechanical ventilation, and death) to indicate severe disease. Becchetti et al. (2020) is a multicentre, prospective study recruiting patients from 19 secondary and tertiary liver transplant centres across Europe, from Inselspital, University Hospital of Bern being the coordinating centre. Only patients older than 18 years of age are included. ICU = intensive care unit; NR = not reported; only Berne being the coordinating centre. Only patients older than 18 years

References

[1] Merola J, Schilsky M, Mulligan D. The impact of COVID-19 on organ donation, procurement, and liver transplantation in the United States. Hepatol Commun 2020. doi: 10.1002/hep.41620.

[2] Chen F, Chen W, Chen J, Xu D, Xie W, Wang X, et al. Clinical features and risk factors of COVID-19-associated liver injury and function: a retrospective analysis of 830 cases. Ann Hepatol 2021;21:100267. doi:10.1016/j.aohep.2020.09.011.

[3] Wong Y, Tan M, Zheng Q, Li JW, Kumar R, Fock KM, et al. A systematic review and meta-analysis of the COVID-19 associated liver injury. Ann Hepatol 2020;19:627–34. doi: 10.1016/j.aohep.2020.08.064.

[4] Colmenero J, Rodríguez-Peralvárez M, Salcedo M, Salcedo M, Arias-Milla A, Muñoz-Serrano A, et al. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients. J Hepatol 2020;74:148–55. doi: 10.1016/j.jhep.2020.07.040.

[5] Rabiee A, Sadowki B, Adeniji N, Perumalswawmi PV, Nguyen V, Moghe A, et al. Liver Injury in Liver Transplant Recipients With Coronavirus Disease 2019 (COVID–19): U.S. Multicenter Experience. Hepatology 2020;72:1900–11. doi: 10.1002/hep.31574.

[6] Belsky J, Tuliuiss B, Lamb M, Sayegh R, Stanek J, Auletta J. COVID-19 in solid organ transplant patients. J. Infect. 2021. doi:10.1016/j.jinf.2021.01.022.

[7] Raja M, Mendoza M, Villavicencio A, Anjan S, Reynolds JM, Kittiapipl V, et al. COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis of current literature. Transplant Rev 2021;35(1):100588. doi: 10.1016/j.trre.2020.100588.

[8] Belsky J, Tuliuiss B, Lamb M, Sayegh R, Stanek J, Auletta J. COVID-19 and the liver: little cause for concern. The Lancet Gastroenterol. Hepatol. 2020;5:529–30.

[9] Ng A. Liver injury in liver transplant patients with COVID-19: a histopathological confirmation. Clin. Gastroenterol. Hepatol. 2021. doi: 10.1016/j.cgh.2021.02.016.

[10] Jaffe A, Schilsky M, Deshpande R, Batra R. Liver Transplantation in the Time of COVID19: barriers and Ethical Considerations for Management and Next Steps. Hepatol Commun 2020;4:1242–56. doi: 10.1002/hep.41588.

[11] Kim D, Yoon S, Ji S, Yang J, Kim Y, Lee S, et al. Ursodeoxycholic acid improves liver function via phenylalanine/tyrosine pathway and microbiome remodelling in patients with liver dysfunction. Sci Rep 2018;8(1). doi: 10.1038/s41598-018-30349-1.

[12] Leuschner U, Lindenthal B, Herrmann G, Arnold J, Rößler M, Cordes H, et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 2010;52(2):472–9. doi: 10.1002/hep.23727.

[13] Thes J, Tekløe J, Clausen U, Tøx U, Klar E, Hofmann WJ, et al. The efficacy of N-acetylcysteine as a hepatoprotective agent in liver transplantation. Transpl Int 1998;11 Suppl 1):S390–2. doi: 10.1007/s001340050505.

[14] Hilmi IA, Peng Z, Panniscn RM, Damaan D, Dai F, Tyurina YY, et al. N-acetylcysteine does not prevent hepatorenal ischaemia-reperfusion injury in patients undergoing orthotopic liver transplantation. Nephrol Dial Transplant 2010;25(7):2328–33. doi: 10.1093/ndt/gfq077.

[15] Manini M, Sangiovanni A, Martiñetti L, Viganó D, La Mura V, Aghemo A, et al. Transarterial chemoembolization with drug-eluting beads is effective for the maintenance of the Milan-in status in patients with a small hepatocellular carcinoma. Liver Transpl. 2015;21(10):1259–69. doi: 10.1002/lt.24196.

[16] Marjot T, Moon A, Cook J, Abd-Elsalam S, Aloman C, Armstrong MJ, et al. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study. J Hepatol 2021;74(3):567–77. doi: 10.1016/j.jhep.2020.09.024.

[17] Li M, Li Z, Zhang Y, Wang X. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty 2020;9(1). doi: 10.1186/s40249-020-00662-x.

[18] Solanich X, Antóli A, Padullés N, Fandó-Maresma M, Iriarte A, Mitjavila F, et al. Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: the TACROVID trial protocol. Contemp Clin Trials Commun 2021;21:100716. doi: 10.1016/j.cctrc.2021.100716.

[19] ClinicalTrials.gov [Internet]. Identifier NCT04359290, ruxolitinib for treatment of Covid-19 induced lung injury ARDS (RuXoCoil). Bethesda (MD): National Library of Medicine (US); 2020 Feb 29. 2020 Apr 24 [cited 2021 Apr 14]; [about 3 screens]. Available from: https://clinicaltrials.gov/ct2/show/NCT04359290.

[20] Ng A. Clinical efficacy of tofacitinib in moderate to severe ulcerative colitis. J. Croh's Colitis 2021. doi: 10.1093/ecto-jcc/jjab062.

[21] Webb G, Marjot T, Cook JA, Aloman C, Armstrong MJ, Brenner EJ, et al. Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study. Lancet Gastroenterol Hepatol 2020;5(11):1008–16. doi: 10.1016/s2468-1253(20)30271-5.

[22] Dumortier J, Duvoux C, Roux O, Altieri M, Barraud H, Besch C, et al. Covid-19 in liver transplant recipients: the French SOF COVID registry. Clin Res Hepatol Gastroenterol 2021;45(4):101639. doi: 10.1016/j.clinre.2021.101639.

[23] Becchetti C, Zambelli MF, Pasulo L, Donato MF, Invernizzi F, Detty O, et al. COVID-19 in an international European liver transplant recipient cohort. Gut 2020;69(10):1832–40. doi: 10.1136/gutjnl-2020-121923.